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Low birth weight has been shown to be associated with later
renal function, but it is unclear to what extent this is explained
by other established kidney disease risk factors. Here we
investigate the roles of diabetes, hypertension, and obesity
using data from the Medical Research Council National Survey
of Health and Development, a socially stratified sample of
5362 children born in March 1946 in England, Scotland, and
Wales, and followed since. The birth weight of 2192 study
members with complete data was related to three markers of
renal function at age 60–64 (estimated glomerular filtration
rate (eGFR) calculated using cystatin C (eGFRcys), eGFR
calculated using creatinine and cystatin C (eGFRcr-cys), and
the urine albumin–creatinine ratio) using linear regression.
Each 1kg lower birth weight was associated with a
2.25ml/min per 1.73m2 (95% confidence interval 0.80–3.71)
lower eGFRcys and a 2.13ml/min per 1.73m2 (0.69–3.58) lower
eGFRcr-cys. There was no evidence of an association with
urine albumin–creatinine ratio. These associations with eGFR
were not confounded by socioeconomic position and were
not explained by diabetes or hypertension, but there was
some evidence that they were stronger in study members
who were overweight in adulthood. Thus, our findings
highlight the role of lower birth weight in renal disease and
suggest that in those born with lower birth weight particular
emphasis should be placed on avoiding becoming
overweight.
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There is increasing recognition of the importance of early life
factors in adult renal disease. A recent meta-analysis has
shown that low birth weight is associated with later kidney
disease in middle-aged and older populations.1 However, it
is, to date, unclear to what extent this association is explained
by adverse circumstances of the mother in pregnancy (via
programming) or of the child or young adult.
Low birth weight has been found, in many studies, to be
associated with later higher blood pressure2–4 and with
the development of type 2 diabetes.5,6 Hypertension and
diabetes are major risk factors for the development of kidney
disease at older ages,7,8 and thus may lie on the causal
pathway between low birth weight and chronic kidney disease
(CKD).
There is mounting evidence that adult obesity increases
the risk of kidney disease.9 In addition, some studies have
found accelerated childhood weight gain to amplify the
association between birth weight and diabetes.10 Obesity thus
appears to be important in the interrelation of birth weight,
diabetes, and renal disease, being both a risk factor for renal
disease in its own right and a modifier of the birth
weight–diabetes association.
The possible pathophysiological pathways between birth
weight and reduced renal function include intrauterine
growth restriction (as evidenced by lower birth weight)
leading to a lower nephron number, glomerular hyperfiltra-
tion later in life, and subsequent increased risk of CKD. The
importance of a lower nephron number has been highlighted
in adults with primary hypertension.11
The Medical Research Council National Survey of Health
and Development (NSHD) provides a unique opportunity
to explore the pathways by which low birth weight is
associated with later kidney function. This study is a
prospective cohort representative of the British population
that has measured birth weight, subsequent anthropometric
markers of growth and weight gain, blood pressure during
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adulthood, and has documented social circumstances
throughout life. Data collected at the age of 60–64 years
allow us to assess albuminuria and estimated glomerular
filtration rate (eGFR). An additional advantage is that this
study has measurements of serum cystatin C as well as serum
creatinine, which has been suggested as a superior marker
of kidney function, with combined creatinine–cystatin C
equations recently found to perform better than equations
based on either of these markers alone.12 We have previously
shown that study members becoming overweight in
early adulthood (age 26 or 36 years) were at a greater
risk of CKD than those who became overweight later in
adulthood.13 We hypothesized that any effect of low
birth weight on later renal function would be mainly
explained by blood pressure and diabetes, and that birth
weight–renal function associations would be stronger in
overweight adults.
RESULTS
Data on one or more of the renal function measures at the age
of 60–64 years (eGFR calculated using cystatin C alone
(eGFRcys), eGFR calculated using cystatin C in combination
with creatinine (eGFRcr-cys), and urine albumin–creatinine
ratio (uACR)) were available for 2198 study members; birth
weight data were also available for 2192 members. Mean birth
weight in the cohort was 3.38 kg (s.d. 0.54), mean eGFRcys
was 94.3ml/min per 1.73m2 (s.d. 14.4), mean eGFRcr-cys was
95.2ml/min per 1.73m2 (s.d. 13.3), and median uACR was
0.55mg/mmol (interquartile range 0.43; Table 1). Using the
KDIGO (Kidney Disease: Improving Global Outcomes)
definition of CKD as eGFR o60ml/min per 1.73m2,14 35
out of 2052 (1.7%) study members had CKD using eGFRcys
and 24 out of 1848 (1.3%) had CKD using eGFRcr-cys.
In childhood, almost 60% of study members were of
manual social class, but by the age of 53 years this had
Table 1 | Distributions of birth weight, kidney function, and potential confounder or mediator variables in the MRC National
Survey of Health and Development
Males Females Total
Variable N Mean (s.d.) N Mean (s.d.) N Mean (s.d.)
Birth weight (kg) 2798 3.44 (0.56) 2529 3.30 (0.51) 5327 3.38 (0.54)
Cystatin C–based eGFR at age 60–64 years (ml/min per 1.73m2) 996 97.0 (14.3) 1056 91.8 (14.1) 2052 94.3 (14.4)
Creatinine and cystatin C–based eGFR at age 60–64 years (ml/min per 1.73m2) 908 95.9 (12.7) 940 94.6 (13.8) 1848 95.2 (13.3)
Log-urine albumin–creatinine ratio at age 60–64 years (mg/mmol) 1042  0.57 (0.82) 1131  0.42 (0.63) 2173  0.49 (0.73)
HbA1c at age 60–64 years (%)a 989 5.86 (0.76) 1056 5.84 (0.66) 2045 5.85 (0.71)
Systolic blood pressure at age 60–64 years (mmHg) 1062 137.5 (18.0) 1147 130.5 (17.3) 2209 133.9 (18.0)
Diastolic blood pressure at age 60–64 years (mmHg) 1062 78.3 (9.9) 1147 74.5 (9.6) 2209 76.3 (9.9)
N n (%) N n (%) N n (%)
Childhood socioeconomic position (age 4 years) 2355 2145 4500
I and II 523 (22.2) 487 (22.7) 1010 (22.4)
III Nonmanual 432 (18.3) 392 (18.3) 824 (18.3)
III Manual 732 (31.1) 689 (32.1) 1421 (31.6)
IV and V 668 (28.4) 577 (26.9) 1245 (27.7)
Adulthood socioeconomic position (age 53 years) 1418 1463 2881
I and II 836 (59.0) 824 (56.3) 1660 (57.6)
III Nonmanual 266 (18.8) 346 (23.7) 612 (21.2)
III Manual 232 (16.4) 161 (11.0) 393 (13.6)
IV and V 84 (5.9) 132 (9.0) 216 (7.5)
Self-reported diabetes by age 60–64 years 1180 1273 2453
No 1079 (91.4) 1191 (93.6) 2270 (92.5)
Yes 101 (8.6) 82 (6.4) 183 (7.5)
On diabetes treatment at age 60–64 years 1268 1358 2626
No 1182 (93.2) 1301 (95.8) 2483 (94.6)
Yes 86 (6.8) 57 (4.2) 143 (5.4)
Midlife systolic blood pressure trajectoryb 1840 1819 3659
Normal 1736 (94.3) 1687 (92.7) 3423 (93.6)
Increaser/high 104 (5.7) 132 (7.3) 236 (6.4)
On hypertension treatment at age 60–64 years 1268 1358 2626
No 862 (68.0) 985 (72.5) 1847 (70.3)
Yes 406 (32.0) 373 (27.5) 779 (29.7)
Overweight at age 36 years 1632 1648 3280
No 913 (55.9) 1221 (74.1) 2134 (65.1)
Yes 719 (44.1) 427 (25.9) 1146 (34.9)
Abbreviations: eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; MRC, Medical Research Council.
aHbA1c (mmol/mol)¼ (HbA1c (%) 2.15)10.929.
bLatent trajectories previously derived from systolic blood pressure data at ages 36, 43, and 53 years.15
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reduced to 21%. Over 6% of the study members were in the
increaser or high midlife systolic blood pressure (SBP) latent
trajectory (previously derived from SBP data at ages 36, 43,
and 53 years15). By the age of 60–64 years, 7% of the study
members reported being diagnosed with diabetes, 5% were
on diabetes treatment, and 30% were on antihypertensive
treatment. Mean glycated hemoglobin (HbA1c) was 5.8%
(s.d. 0.7; 40.4mmol/mol (s.d. 7.7)), mean SBP was 134mm
Hg (s.d. 18), and mean diastolic blood pressure (DBP) was
76.3mmHg (s.d. 9.9). In all, 44% of men and 26% of women
were overweight at the age of 36 years.
The distributions of the three renal outcome variables
(eGFRcys, eGFRcr-cys, and log-uACR), HbA1c, SBP, and
DBP were examined by quartiles of birth weight for men and
women (Supplementary Information and Supplementary
Table S1 online). There were clear trends of higher eGFR
and lower log-uACR, HbA1c, and SBP with higher birth
weight, although these varied somewhat by sex.
Associations between birth weight and each renal out-
come, potential confounder (childhood socioeconomic posi-
tion (SEP)), and potential mediator (adulthood SEP,
overweight at the age of 36 years, self-reported diabetes by
the age of 60–64 years, on diabetes treatment at the age of
60–64 years, HbA1c at the age of 60–64 years, midlife SBP
trajectory, on antihypertensive treatment at the age of 60–64
years, SBP at the age of 60–64 years, DBP at the age of 60–64
years) were examined using all available data (Table 2).
eGFRcys, eGFRcr-cys, and, to a lesser extent, log-uACR at the
age of 60–64 years were associated with birth weight. Each
1 kg lower birth weight was associated with 2.02ml/min per
1.73m2 (95% confidence interval (CI) 0.79–3.25) lower
eGFRcys, 1.88ml/min per 1.73m2 (95% CI 0.66–3.11) lower
eGFRcr-cys, and 0.055 log-mg/mmol (95% CI  0.007 to
0.118) higher log-uACR. Lower birth weight increased the
odds of diabetes by both self-report and treatment, and was
somewhat associated with higher HbA1c at the age of 60–64
years. Lower birth weight was also associated with being in
the increaser/high midlife SBP trajectory and being on antihy-
pertensive treatment, as well as with higher SBP at the age of
60–64 years, but not with DBP. Those with lower birth weight
also had lower odds of being overweight at the age of 36 years.
Associations between each potentially confounding or
mediating variable and each renal outcome were examined
using linear regression and all available data (Table 3). There
was evidence that childhood SEP was associated with renal
function, with more manual occupations associated with
lower eGFR and higher log-uACR. Stronger trends were seen
for adulthood SEP with both eGFR measures, but not with
log-uACR. All three indicators of diabetes/dysglycemia were
only weakly associated with lower eGFR, but strongly
Table 2 | Bivariate regression models for a 1-kg increase in birth weight
Outcome N Coeff 95% CI P overalla
Cystatin C–based eGFR at age 60–64 years (ml/min per 1.73m2)b 2046 2.02 0.79 to 3.25 0.001
Creatinine and cystatin C–based eGFR at age 60–64 years (ml/min per 1.73m2)b 1842 1.88 0.66 to 3.11 0.003
Log-urine albumin–creatinine ratio at age 60–64 years (mg/mmol)b 2167  0.055  0.118 to 0.007 0.08
HbA1c at age 60–64 years (%)b,c 2024  0.060  0.123 to 0.003 0.06
Systolic blood pressure at age 60–64 years (mmHg)b 2169  2.22  3.72 to  0.72 0.004
Diastolic blood pressure at age 60–64 years (mmHg)b 2169  0.18  1.01 to 0.65 0.67
Outcome N OR 95% CI Pa
Childhood socioeconomic position (age 4 years)d 2030 0.04
I and II (Ref)
III Nonmanual 0.75 0.57 to 0.97
III Manual 0.86 0.68 to 1.09
IV and V 0.71 0.56 to 0.91
Adulthood socioeconomic position (age 53 years)d 2050 0.36
I and II (Ref)
III Nonmanual 1.12 0.90 to 1.40
III Manual 0.85 0.64 to 1.13
IV and V 1.14 0.78 to 1.66
Self-reported diabetes by age 60–64 years (yes vs. no)e 1998 0.66 0.46 to 0.94 0.02
On diabetes treatment at age 60–64 years (yes vs. no)e 2192 0.50 0.34 to 0.74 0.001
Midlife systolic blood pressure trajectory (increaser/high vs. normal)e,f 2173 0.71 0.50 to 1.02 0.07
On hypertension treatment at age 60–64 years (yes vs. no)e 2192 0.79 0.66 to 0.96 0.01
Overweight at age 36 years (yes vs. no)e 1994 1.35 1.12 to 1.64 0.002
Abbreviations: CI, confidence interval; Coeff, coefficient; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; OR, odds ratio; Ref, reference.
Restricted to study members non-missing for at least one measure of renal function at the age of 60–64 years.
All models adjusted for sex. Models with outcomes at the age of 60–64 years additionally adjusted for age at measurement.
aLikelihood ratio test.
bLinear regression.
cCoeff with HbA1c (mmol/mol) as outcome¼Coeff with HbA1c (%) as outcome 10.929.
dMultinomial logistic regression.
eLogistic regression.
fLatent trajectories previously derived from systolic blood pressure data at ages 36, 43, and 53 years.15
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associated with higher log-uACR. Being in the increaser/high
midlife SBP trajectory or on antihypertensive treatment was
associated with lower eGFR and higher log-uACR, although
higher SBP at the age of 60–64 years was only associated with
higher log-uACR. Being overweight at the age of 36 years was
strongly associated with lower eGFR and higher log-uACR.
To better understand by which pathways low birth weight
was associated with renal function, subsequent analyses
sequentially adjusted associations between birth weight and
each outcome using study members with complete data on
all variables (Table 4). For both measures of eGFR,
adjustment for childhood and adulthood SEP attenuated
the minimally adjusted associations with birth weight to a
very small extent (model 2; from 2.25 (95% CI 0.80–3.71)
and 2.13 (95% CI 0.69–3.58)ml/min per 1.73m2 per kg
higher birth weight to 2.19 (95% CI 0.73–3.64) and 2.09
(95% CI 0.65–3.54)ml/min per 1.73m2 for eGFRcys and
eGFRcr-cys, respectively). Further adjustment for diabetes
(model 3) had a greater effect (to 2.05 (95% CI 0.60–3.50)
and 1.97 (95% CI 0.52–3.42)ml/min per 1.73m2), as did
adjustment for hypertension (model 4; to 2.07 (95% CI
0.62–3.51) and 2.01 (95% CI 0.57–3.46)ml/min per 1.73m2).
Adjustment for overweight at the age of 36 years (model 5)
amplified the associations somewhat (to 2.41 (95% CI
0.96–3.86) and 2.31 (95% CI 0.86–3.76)ml/min per
1.73m2). The fully adjusted models (model 6) thus showed
Table 3 | Bivariate linear regression models for associations with renal function at the age of 60–64 years
Outcome Explanatory variable N Coeff 95% CI P overalla P trenda
Cystatin C–based eGFR
at age 60–64 years (ml/min per 1.73m2)
Childhood socioeconomic position (age 4 years) 1898 0.003 0.001
I and II (Ref)
III Nonmanual 0.07  1.80 to 1.95
III Manual  2.55  4.26 to  0.84
IV and V  2.20  3.97 to  0.42
Adulthood socioeconomic position (age 53 years) 1917 o0.001 o0.001
I and II (Ref)
III Nonmanual  2.44  4.00 to  0.88
III Manual  3.14  5.21 to  1.08
IV and V  3.19  5.96 to  0.52
Self-reported diabetes by age 60–64 years (yes vs. no) 1871  3.07  5.70 to  0.44 0.02
On diabetes treatment at age 60–64 years (yes vs. no) 2046  3.02  5.94 to  0.10 0.04
HbA1c at age 60–64 years (per %)b 1964  0.77  1.67 to 0.12 0.09
Midlife systolic blood pressure trajectory (increaser/high vs. normal)c 2027  3.26  5.85 to  0.67 0.01
On hypertension treatment at age 60–64 years (yes vs. no) 2046  3.69  5.03 to  2.35 o0.001
Systolic blood pressure at the age of 60–64 years (per 20mmHgd) 2027 0.48  0.22 to 1.17 0.18
Diastolic blood pressure at age 60–64 years (per 10mmHgd) 2027 0.70 0.07 to 1.32 0.03
Overweight at age 36 years (yes vs. no) 1863  3.58  4.97 to  2.20 o0.001
Creatinine and cystatin C–based eGFR at
age 60–64 years (ml/min per 1.73m2)
Childhood socioeconomic position (age 4 years) 1708 0.30 0.13
I and II (Ref)
III Nonmanual 0.20  1.64 to 2.04
III Manual  1.24  2.92 to 0.45
IV and V  0.97  2.74 to 0.80
Adulthood socioeconomic position (age 53 years) 1739 0.01 0.001
I and II (Ref)
III Nonmanual  1.86  3.42 to  0.29
III Manual  2.15  4.27 to  0.02
IV and V  3.06  5.76 to  0.37
Self-reported diabetes by age 60–64 years (yes vs. no) 1689  2.17  4.85 to 0.50 0.11
On diabetes treatment at age 60–64 years (yes vs. no) 1842  3.71  6.68 to  0.74 0.01
HbA1c at age 60–64 years (per %)b 1768  1.26  2.17 to  0.35 0.007
Midlife systolic blood pressure trajectory (increaser/high vs. normal)c 1825  3.15  5.70 to  0.59 0.02
On hypertension treatment at age 60–64 years (yes vs. no) 1842  3.65  4.99 to  2.31 o0.001
Systolic blood pressure at age 60–64 years (per 20mmHgd) 1826 0.28  0.41 to 0.97 0.42
Diastolic blood pressure at age 60–64 years (per 10mmHgd) 1826 0.35  0.28 to 0.97 0.28
Overweight at age 36 years (yes vs. no) 1676  3.33  4.71 to  1.95 o0.001
Log-urine albumin–creatinine ratio at
age 60–64 years (mg/mmol)
Childhood socioeconomic position (age 4 years) 2006 0.09 0.01
I and II (Ref)
III Nonmanual 0.021  0.074 to 0.117
III Manual 0.081  0.006 to 0.167
IV and V 0.101 0.011 to 0.191
Adulthood socioeconomic position (age 53 years) 2027 0.15 0.32
I and II (Ref)
III Nonmanual 0.010  0.070 to 0.090
III Manual 0.118 0.013 to 0.223
IV and V  0.030  0.167 to 0.107
Self-reported diabetes by age 60–64 years (yes vs. no) 1974 0.286 0.157 to 0.414 o0.001
On diabetes treatment at age 60–64 years (yes vs. no) 2167 0.410 0.269 to 0.551 o0.001
HbA1c at age 60–64 years (per %)b 2001 0.123 0.078 to 0.167 o0.001
Midlife systolic blood pressure trajectory (increaser/high vs. normal)c 2149 0.316 0.187 to 0.445 o0.001
On hypertension treatment at age 60–64 years (yes vs. no) 2167 0.202 0.134 to 0.269 o0.001
Systolic blood pressure at age 60–64 years (per 20mmHgd) 2144 0.116 0.081 to 0.150 o0.001
Diastolic blood pressure at age 60–64 years (per 10mmHgd) 2144 0.066 0.035 to 0.098 o0.001
Overweight at age 36 years (yes vs. no) 1971 0.140 0.069 to 0.210 o0.001
Abbreviations: CI, confidence interval; Coeff, coefficient; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; Ref, reference.
Restricted to study members nonmissing for birth weight.
All models adjusted for sex and age at renal function measurement.
aLikelihood ratio test.
bHbA1c (mmol/mol) coeff¼HbA1c (%) coeff/10.929.
cLatent trajectories previously derived from systolic blood pressure data at ages 36, 43, and 53 years.15
dApproximately 1 s.d.
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similar associations between birth weight and eGFR to the
minimally adjusted models (2.24 (95% CI 0.80–3.69) and
2.15 (95% CI 0.71–3.60)ml/min per 1.73m2). Among
study members with complete data on all variables,
there was no evidence of an association between birth
weight and log-uACR ( 0.019 (95% CI  0.094 to 0.056)
log-mg/mmol per kg higher birth weight). Adjustment for
SEP, diabetes, and hypertension attenuated this effect even
further toward zero.
Fully adjusted models stratified by overweight status at the
age of 36 years are presented in Table 5. In study members
who were overweight at the age of 36 years, the association
between birth weight and eGFR was much stronger than in
those who were not overweight (3.14 (95% CI 0.47–5.82) vs.
1.79 (95% CI 0.17–3.41)ml/min per 1.73m2 per 1 kg higher
birth weight for eGFRcys and 4.03 (95% CI 1.34–6.71) vs.
1.03 (95% CI  0.59 to 2.65)ml/min per 1.73m2 for eGFRcr-
cys). Evidence for this effect modification was stronger for
eGFRcr-cys (P¼ 0.01 by Wald test) than for cystatin C based
(P¼ 0.08). However, there was little evidence of effect
modification by overweight at the age of 36 years when
considering log-uACR (P¼ 0.31). Similar results were
obtained for effect modification by overweight at ages 43
and 53 years (not shown).
The subset of study members with complete data are likely
to be a more health-conscious subgroup who have adhered to
follow-up for over 60 years, and thus potentially unrepre-
sentative of the cohort as a whole. An analysis of only
complete cases may therefore provide biased results. We used
multiple imputation (MI)16,17 to explore the robustness of
the complete case results to this potential bias (for full detailsT
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Table 5 | Linear regression models for a 1-kg increase in birth
weight by overweight status at the age of 36 years
Outcome
Overweight
at age
36 years N Coeff 95% CI Pa
Cystatin C–based eGFR No 1076 1.79 0.17 to 3.41 0.03
(ml/min per 1.73m2) Yes 495 3.14 0.47 to 5.82 0.02
Creatinine and No 979 1.03  0.59 to 2.65 0.21
cystatin C–based eGFR
(ml/min per 1.73m2)
Yes 445 4.03 1.34 to 6.71 0.003
Log-urine No 1088 0.017  0.062 to 0.096 0.68
albumin–creatinine
ratio (mg/mmol)
Yes 504  0.042  0.192 to 0.108 0.58
Abbreviations: CI, confidence interval; Coeff, coefficient; eGFR, estimated glomerular
filtration rate; HbA1c, glycated hemoglobin.
Restricted to study members nonmissing for childhood and adulthood
socioeconomic status, self-reported diabetes by the age of 60–64 years, on diabetes
treatment at the age of 60–64 years, HbA1c at the age of 60–64 years, midlife
systolic blood pressure trajectory, on hypertension treatment at the age of 60–64
years, and systolic blood pressure at the age of 60–64 years.
Models adjusted for sex, age at renal function measurement, childhood and
adulthood socioeconomic position, self-reported diabetes by the age of 60–64
years, on diabetes treatment at the age of 60–64 years, HbA1c at the age of 60–64
years, midlife systolic blood pressure trajectory, on hypertension treatment at the
age of 60–64 years, systolic blood pressure at the age of 60–64 years, and diastolic
blood pressure at the age of 60–64 years.
Wald test for effect modification by overweight status at the age of 36 years:
P¼ 0.08 for cystatin C–based eGFR; P¼ 0.01 for creatinine and cystatin C–based
eGFR; P¼ 0.31 for log-urine albumin–creatinine ratio.
aLikelihood ratio test.
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see the Materials and Methods section). The entire analysis
was repeated using MI, with the results being very similar to
those obtained in the complete case analysis overall
(Supplementary Information and Supplementary Tables
S2–S5 online). The associations between birth weight and
eGFR were slightly weaker in the MI analysis, and that with
log-uACR was markedly stronger (although there was little
evidence for this association under either approach once
diabetes and/or hypertension were adjusted for). Conclusions
in both analyses were identical.
DISCUSSION
In this large, population-based, prospective study, we found
lower birth weight to be associated with eGFR, although not
with uACR, measured over 60 years later. The associations
with eGFR were not confounded by SEP and were not
explained by diabetes or hypertension. There was some
evidence that the associations were stronger in study
members who were overweight in adulthood.
A recent systematic review and meta-analysis found low
birth weight to be associated with later kidney disease in
middle-aged and older populations.1 Although the estimated
associations in the present analysis are not directly
comparable with the meta-analysis as the latter used
dichotomous classifications of both birth weight and CKD,
the results are clearly in the same direction. White et al.1
suggested that further studies should consider important
confounders, such as socioeconomic factors. In the present
study, we did not find SEP to be a strong confounder of the
birth weight–renal function association.
Low birth weight has been found in many studies to be
associated with later blood pressure2–4 and with the
development of type 2 diabetes.5,6 Associations between
birth weight and self-reported diabetes by the age of 60–64
years, being on diabetes treatment at the age of 60–64 years,
midlife SBP trajectory, and being on antihypertensive
treatment at the age of 60–64 years were found in this study.
Associations with HbA1c and SBP at the age of 60–64 years
were weaker but in the expected direction.
Hypertension, diabetes (especially longer duration of
diabetes), and adulthood overweight are all acknowledged
risk factors for the development of kidney disease at older
ages, and thus may lie on the causal pathway between birth
weight and CKD.7–9 However, lower birth weight is associated
with lower adulthood weight.18 Hence, although people with
lower birth weight are at a higher risk of hypertension and
diabetes (and thus CKD), this is, to a greater or lesser extent,
counterbalanced by adulthood overweight (and the
corresponding increased risk of CKD) being less frequent in
those with lower birth weight.
To better understand the mechanisms by which low birth
weight is associated with renal function, it would be
important to distinguish between two causes of low birth
weight: (1) preterm birth and (2) intrauterine growth
restriction.19,20 This study did not collect data on
gestational age, and thus does not allow us to disentangle
whether the associations found are related to prematurity or
intrauterine growth restriction. However, survival rates
among preterm births would have been low in the 1940s,
and thus it is likely that most of the variation in birth weights
was due to (relative) intrauterine growth restriction. Animal
models suggest that prematurity is associated with abnormal
glomeruli,21 and that early timing of intrauterine growth
restriction leads to reduced nephron number.22 These
observations, together with our data, lead us to speculate
whether a prolonged increased filtration load in overweight
individuals (over several decades of overweight) could lead to
a faster decline of kidney function with age, through faster
sclerosis of abnormal and/or fewer glomeruli. Autopsy
studies in humans would be consistent with such a
speculation.23 In children with proteinuric kidney disease,
obesity together with lower-term birth amplifies progression
of the existing kidney disease, which would fit to our finding
for the general population.24
Although we found strong evidence of an association
between birth weight and GFR, the evidence of an association
between birth weight and albuminuria was much weaker. We
suggest that this may be because those with low birth weight
who had albuminuria have already decreased their renal
function and/or got blood pressure treatment by the time of
follow-up. However, we cannot prove this in this study, as we
do not have the necessary historical data.
We estimated a 1-kg difference in birth weight to be
associated with a42ml/min per 1.73m2 difference in eGFR.
Although this effect seems small at an individual level, such a
difference in eGFR across a population would decrease the
burden of CKD considerably. Such a difference, and the
associated implications on CVD risk, would be felt
particularly keenly in low- to middle-income countries where
a high prevalence of low birth weight is now often followed
by rapid growth, leading to overweight in adult life.
A significant strength of this study is that all data were
collected prospectively using standardized protocols over
60–64 years. We were able to adjust for all the major potential
confounding or mediating factors, although we acknowledge
that for some of these a degree of residual confounding may be
present. In particular, adjustment for SEP at only two ages may
not be sufficient to fully account for the effect of SEP (and
associated adverse circumstances) over the life course. There
may, in addition, be residual confounding by parental factors
for which data were not available, including kidney disease,
diabetes mellitus, preeclampsia, hypertension, and smoking.
The availability of multiple measures of renal function
(eGFRcys, eGFRcr-cys, and uACR) facilitated a thorough
analysis, although the lack of repeated measurements of these
measures, as required under the recommended definition of
CKD,14 meant that our outcome measures were susceptible to
relatively greater measurement error. However, we believe that
any outcome measurement error would be independent of
birth weight, and thus this should not lead to bias in the results.
The cohort members remaining in the NSHD have been
found to be broadly representative of native-born adults
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living in England, Scotland, and Wales at the time of data
collection at the age of 53 years25 and at the age of 60–64
years.26 Hence, we are confident that our analysis sample
retains the representativeness of the study population as a
whole. The NSHD study population is, however, all white,
and therefore our findings cannot be extrapolated to the non-
white British population. In addition, the NSHD is a
relatively healthy cohort in terms of CKD prevalence, and
thus it is unclear whether our findings would extrapolate to
other settings. Further studies in such settings are required.
The use of MI allowed us to investigate the role of
incomplete follow-up on the results. Although there were
some differences between specific MI and complete case
models, results were very similar overall and led to identical
conclusions. MI analyses rest on the untestable assumption of
data being ‘missing at random,’27 but we believe that we
included sufficient variables in our imputation model that
are predictive of missing values or the processes causing
missingness to make this assumption plausible.
In conclusion, we have found lower birth weight to be
associated with reduced kidney function over 60 years later,
particularly in those who become overweight by early
adulthood. This association was not confounded by SEP
and was not explained by diabetes or SBP. In those born with
low birth weight, particular emphasis should be placed on
avoiding the deleterious effects of becoming overweight.
MATERIALS AND METHODS
Participants
The Medical Research Council (MRC) NSHD is a socially stratified
sample of 5362 singleton children born in 1 week in March 1946 in
England, Scotland, and Wales, who have been followed up many
times since birth.28 Between October 2006 and February 2011 (at
60–64 years), 2856 eligible study members (those known to be alive
and with a known address in England, Scotland, or Wales) were
invited for an assessment at one of six Clinical Research Facilities.
Invitations were not sent to those who had died (n¼ 778), were
living abroad (n¼ 570), had previously withdrawn from the study
(n¼ 594), or had been lost to follow-up (n¼ 564). If study members
were unable or unwilling to come to one of the Clinical Research
Facilities, they were offered a slightly less comprehensive examina-
tion carried out in their own home by a trained nurse. Of those
invited, 2229 (78.0%) were assessed: 1690 (59.1%) attended a clinic
and 539 (18.9%) had a home visit.26
Measures
At the clinic or home visit at the age of 60–64 years, blood and urine
samples were taken and processed according to standardized
protocols. Serum creatinine was measured by means of a kinetic
version of the Jaffe method using a Siemens (Munich, Germany)
Dimension Xpand analyzer at the MRC Human Nutrition Research
laboratory in Cambridge. Cystatin C was measured by an automated
particle enhanced immunoturbidimetric assay at the Glasgow Royal
Infirmary, Department of Clinical Biochemistry. Urine creatinine
was measured using a kinetic version of the Jaffe method on a
Siemens Dimension analyzer, and urinary albumin was measured by
an immunoturbidimetric method on a Siemens BNII/ProSpec
analyzer at the MRC Human Nutrition Research laboratory in
Cambridge.
eGFR was calculated using two approaches: (1) using cystatin C
alone and (2) using cystatin C in combination with creatinine, both
using the formulae of Inker et al.12 These formulae, particularly the
combined creatinine and cystatin C version, have been found to
perform better than those previously derived.12 uACR was calculated
with adjustment for storage time. log-uACR was used in all analyses
owing to the skewed distribution of uACR.
Birth weight of study members, to the nearest quarter of a
pound, was extracted from medical records within a few weeks of
delivery and converted into kg.
Childhood SEP was derived from the father’s reported occupa-
tion when the study participant was aged 4; adulthood SEP was
defined as the highest occupational class derived from the study
participant’s and their spouse’s reported occupations at the age of 53
years. SEP classification was based on the British Registrar General’s
Social Classification:29 ‘I and II professional and managerial,’ ‘III
non-manual,’ ‘III manual skilled,’ or ‘IV and V manual semi or
unskilled.’
Adult heights and weights were measured at the ages of 36, 43
and 53 years. Body mass index, defined as weight (kg)/height (m)2,
was calculated at each age, with a binary variable indicating over-
weight derived at each age using the standard cut point of 25 kg/m2.
Diabetes (self-reported doctor-diagnosed diabetes by the age of
60–64 years, being on diabetes treatment at the age of 60–64 years,
and HbA1c level at the age of 60–64 years) and hypertension
(previously derived SBP latent trajectory between ages 36 and 53
years,15 being on antihypertensive treatment at the age of 60–64
years, and measured SBP at the age of 60–64 years) were considered
as mediating factors. HbA1c was analyzed using a Tosoh (Tokyo,
Japan) G7 analyzer at Addenbrooke’s Hospital in Cambridge. Two
measures of SBP at the age of 60–64 years were taken with an Omron
705 (Kyoto, Japan) with the participant seated, with the minimum
reading used in this analysis. The remaining diabetes and
hypertension data were derived from questionnaire responses.
Statistical analyses
Associations between birth weight and each renal outcome
(eGFRcys, eGFRcys, and log-uACR) and between birth weight and
each potential confounder/mediator (childhood and adulthood SEP,
diabetes, hypertension, and overweight at the age of 36 years) were
examined using linear, logistic, or multinomial logistic regression as
appropriate. All models were adjusted for sex, and those with
outcomes at the age of 60–64 years were additionally adjusted for age
at measurement.
Associations between each potential confounding/mediating
variable and each renal outcome were then examined using linear
regression, with all models adjusted for sex and age at renal function
measurement.
Next, using study members with complete data on all variables,
associations between birth weight and each renal outcome were
sequentially adjusted for potential confounding/mediating factors as
follows:
Model 1: minimally adjusted for sex and age at renal function
measurement;
Model 2: model 1þ childhood and adulthood SEP;
Model 3: model 2þ self-reported diabetes by the age of 60–64
yearsþ on diabetes treatment at the age of 60–64 yearsþHbA1c at
the age of 60–64 years;
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Model 4: model 2þmidlife systolic blood pressure trajectoryþ
on antihypertensive treatment at the age of 60–64 yearsþ systolic
blood pressure at the age of 60–64 years;
Model 5: model 2þ overweight at the age of 36 years;
Model 6: model 2þ self-reported diabetes by the age of 60–64
yearsþ on diabetes treatment at the age of 60–64 yearsþHbA1c at
the age of 60–64 yearsþmidlife systolic blood pressure trajectoryþ
on antihypertensive treatment at the age of 60–64 yearsþ systolic
blood pressure at the age of 60–64 yearsþ overweight at the age of
36 years.
Finally, we tested for effect modification by overweight at the age
of 36 years in the fully adjusted model and present results within
each strata of overweight at the age of 36 years separately. This
analysis was repeated to explore effect modification by overweight at
ages 43 and 53 years.
To investigate the potential bias caused by missing data, the
entire analysis was repeated using an MI approach.16,17 MI allows for
uncertainty about missing data by creating several different plausible
imputed data sets and appropriately combining results obtained
from each of them. In addition to all the variables included in the
analysis models, the imputation model also included occupation at
other ages in adulthood, further repeated measures of body mass
index in childhood and adulthood, repeated measures of adulthood
waist–hip ratio, achieved educational levels of the study member and
their parents, and response for data collection at the age of 60–64
years (for example, clinic/home visit, temporary/permanent refusal,
untraced). Interactions with sex were included in the imputation
model for all variables, as well as interactions between birth weight
and body mass index at each age. Study members who were
known to have died before or during data collection at the age of
60–64 years were excluded from the MI analysis. A total of 50
imputed data sets were obtained via chained equations.30
In all models, potential nonlinear effects of the main explanatory
variable were examined by the addition of a quadratic term. Such
nonlinear associations were never observed, and thus linear models
are presented through.
Strong interactions between sex and other explanatory variables
were not found in any of the models, and thus combined male and
female models are presented throughout.
The analysis was performed using Stata 12 (Stata statistical
software, release 12; StataCorp, College Station, TX, 2011).
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